Among its portfolio companies.

Acousticon receives FDA clearance for ACAM-5 hearing reduction product TCG today announced that Acousticon Inc., among its portfolio companies, lately received FDA clearance for its ACAM-5 product, allowing the ongoing organization to begin with US commercialization activities designed for the first time best online pharmacy . The ACAM-5 is normally a German engineered product that helps hearing professionals understand the scope and depth of a patient’s hearing loss to be able to optimize the performance of hearing aids. Robert Keefer, PhD, is President of Acousticon, Inc. And also a Partner at TCG, an international business development, implementation and strategy firm, that has released five European medical companies in the US within the last five years.

Food and Drug Administration seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets. Related StoriesKolltan announces display of data from KTN0158 preclinical research in mast cell tumors at ESMO 2015Allergan settles patent litigation with Amneal related to NAMENDA XR extended discharge capsulesFDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult sufferers with acromegaly On January 18 Endo and Grunenthal GmbH filed match against Actavis, 2013, in the U.S. District Court for the Southern District of New York seeking to prevent Actavis from commercializing its ANDA product before the expiration of specific U.S. Patents.S. Product sales of approximately $512 million regarding to IMS Health data..